Zydus to present on ZYIL1 at the International Congress of Parkinson's Disease and Movement Disorders
In Phase I studies, ZYIL1 was found to be safe and well-tolerated in human volunteers
In Phase I studies, ZYIL1 was found to be safe and well-tolerated in human volunteers
The company is committed to address the observations and will submit its response to US FDA within the stipulated time
First PARP inhibitor approved in Japan to demonstrate clinically meaningful benefits in combination with a new hormonal agent
India will account for about 18% of the Asia-Pacific (APAC) MRI systems market in 2023
Rs. 64000 crores are being invested across the 750 districts of India, to create a more resilient healthcare system in the country
NIH’s candidate is based on the Adenovirus 4 backbone, largely used as a vector candidate in HIV and influenza vaccine clinical trials
Mizoram appoints Youth for Action as the Interfacing Agency for implementing the ABDM Microsite in Aizawl
Guaifenesin extended-release tablets help to loosen phlegm (mucus) and thin bronchial secretions to rid the bronchial passageways of bothersome mucus and make coughs more productive
Jupiter has filed its draft herring prospectus (DRHP) with the market regulator in May this year, to float its IPO
Weinand is the former CEO and Chairman of the Board at Bayer Pharma AG, leading Bayer’s fully integrated $20 billion healthcare business
Subscribe To Our Newsletter & Stay Updated